# M&A AT A GLANCE

**Key Takeaways** 

- ▶ U.S. M&A activity in December increased 12% by total deal value over November activity levels, but declined 34% by deal count. Sponsor and strategic activity mirrored the broader trend, with both sponsor and strategic total deal value increasing 13% and 12%, respectively, while deal count fell 44% and 30%, respectively. Global activity was up 6% by total deal value and down 17% by deal count. Global strategic activity was up 12% by total deal value and down 12% by deal count, while global sponsor activity was down 6% by total deal value and 37% by deal count.
- ▶ U.S. inbound and outbound activity was also mixed in December, up 34% and down 17% by total inbound deal value and deal count, respectively, and up 65% and down 34% by total outbound deal value and deal count, respectively. Japan led inbound activity by total deal value, while the U.K. continued to lead outbound activity by total deal value. In the last twelve months (LTM), Canada led inbound activity by deal count and deal value while the U.K. led outbound activity by the same metrics.
- ► Healthcare was again the most active industry by total deal value in the U.S. (\$43.9 billion), decreasing 1% over November. Computers & Electronics remained the most active industry by deal count in the U.S. for December (148 deals) and continues to lead LTM by total deal value and deal count.
- SPAC acquisitions declined in the U.S., falling 6% by total deal value, and 13% by deal count. Globally, SPAC acquisitions were up, increasing 39% by total deal value and 8% by deal count.
- U.S. public merger highlights in December include the following:
  - Average reverse break fees were 6.6%, an increase versus the LTM average of 6.2%.
  - No strategic deals had a go-shop provision, compared to 5% of such deals LTM, while 33.3% of financial buyer deals had go shops, in line with the 30% LTM.
  - Stock surged as a form of consideration, with both it and cash comprising 46% of the form of consideration, and the remainder being mixed consideration deals (9%).
  - The lack of any tender offers is well below the LTM average of 16% of deals.

# **Strategic vs. Sponsor Activity**


# U.S. Total \$107.4 billion - ▲11.8% 571 deals - ▼34.3% Strategic \$75.8 billion - ▲11.5% 405 deals - ▼29.6% Sponsor \$31.6 billion - ▲12.6% 166 deals - ▼43.5%

Global

S

<b>Total</b>	
\$256.2 billion – ▲6.1%	
2,488 deals - ▼16.9%	
Strategic	
5184.2 billion – ▲11.6%	
2,100 deals – ▼11.9%	
Sponsor	
572.0 billion – ▼5.9%	
888 deals – ▼36.6%	

# **Crossborder Activity**



# **Industry Activity**










## **SPAC Acquisitions**





All data is for December 2022, and is as of January 10, 2023 unless otherwise specified. Each metric in this publication that references deal volume by dollar value is calculated from the subset of the total number of deals that includes a disclosed deal value.

## Most Active U.S. Target Industries<sup>1</sup>



1,000

2,000

3,000

4,000

\$0

\$163

\$325

\$488

\$650

## Average Break Fees as % of Equity Value<sup>2</sup>



# Average Break Fees as % of Equity Value<sup>3,4</sup>


	December 2022	Last 12 Months
Target Break Fee for All Mergers	3.2	3.5
· g		

	December 2022	Last 12 Months
Reverse Break Fee for All Mergers <sup>5</sup>	6.6	6.2
Reverse Break Fee for Mergers Involving Financial Buyers <sup>6</sup>	6.7	6.8
Reverse Break Fee for Mergers Involving Strategic Buyers <sup>7</sup>	6.5	5.6

# U.S. Public Merger Go-Shop Provisions<sup>4</sup>

	December 2022	Last 12 Months
% of Mergers with Go-Shops	9.1	13.2
% of Mergers Involving Financial Buyers with Go- Shops <sup>8</sup>	33.3	30.0
% of Mergers Involving Strategic Buyers with Go- Shops <sup>9</sup>	0.0	4.9
Avg. Go-Shop Window (in Days) for All Mergers with Go-Shops <sup>10</sup>	60.0	36.6
Avg. Go-Shop Window (in Days) for Mergers Involving Financial Buyers with Go-Shops <sup>11</sup>	60.0	37.4
Avg. Go-Shop Window (in Days) for Mergers Involving Strategic Buyers with Go-Shops <sup>12</sup>	N/A	34.0

Form of Consideration as % of U.S. Public Mergers<sup>13</sup>



#### Tender Offers as % of U.S. Public Mergers

December 2022	0.0
Last 12 Months	16.4

### Hostile/Unsolicited Offers as % of U.S. Public Mergers<sup>14</sup>

December 2022	8.3
Last 12 Months	17.9


# Unaffected Premium %14,15

December 2022	58.8
Last 12 Months	49.7


#### Total Target Adviser Fee(s) as % of Equity Value

December 2022	2.1
Last 12 Months	1.5

#### Top 5 Countries of Origin for Inbound U.S. Crossborder Transactions




Top 5 Countries of Destination for Outbound U.S. Crossborder Transactions



# Appendix: M&A Activity – 12 Month Trends

#### U.S. Deal Value (US\$B)



#### Global Deal Value (US\$B)





#### **Global Number of Deals**




#### **Inbound U.S. Crossborder Transactions**





#### **Outbound U.S. Crossborder Transactions**











# **Endnotes**

- 1. Industries categories are determined and named by Cortex.
- 2. Based on the highest target break fees and reverse break fees payable in a particular deal.
- 3. There were 12 transactions in December 2022.
- 4. Financial and strategic categories are determined by Deal Point Data.
- 5. Four transactions in December 2022 had a reverse break fee.
- 6. Two transactions in December 2022 involving a financial buyer had a reverse break fee.
- 7. Two transactions in December 2022 involving a strategic buyer had a reverse break fee.
- 8. Three transactions in December 2022 involved a financial buyer.
- 9. Eight transactions in December 2022 involved a strategic buyer.
- 10. One transactions in December 2022 had a go-shop provision.
- One transactions in December 2022 involving a financial buyer had a go-shop provision.
- 12. No transactions in November 2022 involving a strategic buyer had a go-shop provision.
- 13. Due to rounding, percentages may not add up to 100%.

- 14. This data includes both announced transactions for which a definitive merger agreement was reached and filed and those for which a definitive merger agreement was never reached and filed (including withdrawn transactions).
- 15. Unaffected Premium % indicates the difference between the current price per share offered as consideration in the transaction and the "unaffected price", reflected as a percentage. The "unaffected price" is the target's closing stock price on the date that is one calendar day prior to the first public disclosure regarding a potential deal involving the target and on which the target's stock price was unaffected by the news of the deal.
- In December 2022, each of Brazil, China, Ireland and Sweden was the country of destination for four transactions.
- 17. This data reflects U.S. targets that have been acquired by a SPAC of any nationality.
- 18. This data reflects both U.S. and non-U.S. targets that have been acquired by a SPAC of any nationality.

The charts on p. 1–2 and 5–10 were compiled using Cortex, and are for the broader M&A market, including public and private transactions of any value. Deal volume by dollar value and average value of deals are calculated from the subset of deals that include a disclosed deal value. The charts on p. 3–4 were compiled using Deal Point Data, and include acquisitions seeking majority or higher control of U.S. targets valued at \$100 million or higher announced during the period indicated and for which a definitive merger agreement was reached and filed (except with respect to data regarding premiums and hostile/unsolicited offers, which is for all announced deals). "Last 12 Months" data is for the period from January 2022 to December 2022 inclusive. Data obtained from Cortex and Deal Point Data has not been reviewed for accuracy by Paul, Weiss.

# Our Mergers & Acquisitions Practice

Paul, Weiss is a leading law firm serving the largest publicly and privately held corporations and financial institutions in the United States and throughout the world. Our firm is widely recognized for achieving an unparalleled record of success for our clients, both in their bet-the-company litigations and their most critical strategic transactions. We are keenly aware of the extraordinary challenges and opportunities facing national and global economies and are committed to serving our clients' short- and long-term goals.

The Paul, Weiss M&A Group consists of approximately 40 partners and 125 counsel and associates based in New York, Washington, Wilmington, London, San Francisco, Toronto, Tokyo, Hong Kong and Beijing. The firm's Corporate Department consists of more than 75 partners and roughly 300 counsel and associates.

Our M&A Group is among the most experienced and active in the world. We represent publicly traded and privately held companies, leading private equity firms, financial advisors, and other financial institutions and investors in their most important mergers and acquisitions, joint ventures and other strategic transactions. Our expertise advising corporations and private investors in a broad range of sophisticated transactions enables us to identify new opportunities for our clients to realize value. We have particular experience in guiding clients as they engage in proxy battles, company-altering and market consolidating transactions or capital markets transactions.

#### Strategic M&A

Recent highlights include advising: The special committee of Duck Creek Technologies' board of directors in connection with Duck Creek's \$2.6 billion take-private sale to Vista Equity Partners; The Estée Lauder Companies in its \$2.8 billion acquisition of the Tom Ford brand; Yamana Gold in its \$4.8 billion sale to Pan American Silver and Agnico Eagle Mines; Amazon in its \$3.9 billion acquisition of One Medical and in its \$1.7 billion acquisition of iRobot; Resolute Forest Products in its \$2.7 billion sale to The Paper Excellence Group through the Group's wholly-owned subsidiary, Domtar Corporation; Yamana Gold in its proposed \$6.7 billion sale to Gold Fields; Shopify in its \$2.1 billion acquisition of Deliverr; CDK Global in its \$8.3 billion sale to Brookfield Business Partners; General Motors Co. in its \$3.45 billion acquisition of SoftBank Vision Fund's equity ownership stake and assumption of Softbank's investment obligation in the autonomous vehicle joint venture Cruise; Chevron Corporation in its \$3.15 billion acquisition of Renewable Energy Group; Aptiv in its \$4.3 billion acquisition of Wind River from TPG Capital: Rocket Companies in its \$1,275 billion acquisition of Truebill: General Electric in its reorganization through spin-offs into three separately traded public companies: Qualcomm, alongside SSW Partners, in its \$4.5 billion topping bid for Veoneer; Continental Grain Company in its joint venture with Cargill to acquire Sanderson Farms for a total equity value of \$4.53 billion; Translate Bio in its \$3.2 billion sale to Sanofi; Carrier Global Corporation in the \$3.1 billion sale of its Chubb fire and security business to APi Group Corporation; Bowlero Corp in its \$2.6 billion business combination with Isos Acquisition Corporation; the Special Committee of the Board of Directors of QAD in its \$2 billion sale to Thoma Bravo; QTS Realty Trust in its \$10 billion sale to Blackstone; MGM in its \$8.45 billion sale to Amazon; Lehigh Hanson in the \$2.3 billion sale of its U.S. West region business to Martin Marietta Material; Advance in the \$150 billion Reverse Morris Trust transaction that will combine AT&T's WarnerMedia business with Discovery, Nuance Communications in its \$19.7 billion sale to Microsoft Corp.; General Electric in the more than \$30 billion combination of its jet leasing unit GE Capital Aviation Services (GECAS) with AerCap Holdings; PRA Health Sciences in its approximately \$12 billion sale to ICON; The Goodyear Tire & Rubber Company in its \$2.5 billion acquisition of Cooper Tire & Rubber Company; Perspecta Inc. in its \$7.1 billion sale to Peraton and Veritas Capital; Cenovus Energy in its Cdn. \$23.6 billion combination with Husky Energy; The Kraft Heinz Company in the \$3.2 billion sale of its cheese business to Groupe Lactalis; Teladoc Health in its \$18.5 billion acquisition of Livongo Health; Chevron in its \$13 billion acquisition of Noble Energy; National General Holdings in its \$4 billion sale to The Allstate Corporation; The Medicines Company in its \$9.7 billion sale to Novartis; the Special Committee of the Board of Directors of Pattern Energy Group in its approximately \$6.1 billion sale to Canada Pension Plan Investment Board; the Special Committee of the Board of Directors of CBS Corp. in its merger with Viacom to form ViacomCBS, a combined company with an enterprise value of more than \$40 billion; Elanco Animal Health in its \$7.6 billion acquisition of the animal health business of Bayer AG; the Independent Directors of Avon in its \$3.7 billion sale to Natura & Co.; Trane Technologies in the \$15 billion Reverse Morris Trust spin-off and merger of its industrial business with Gardner Denver Holdings; Chevron in its proposed \$50 billion acquisition of Anadarko Petroleum; General Electric in the \$21.4 billion sale of its BioPharma business to Danaher Corporation; and IBM in its \$34 billion acquisition of Red Hat.

#### Private Equity M&A

Recent highlights include advising: KPS Capital Partners in the \$4.4 billion sale of its portfolio company Howden to Chart Industries; Brookfield Asset Management in its acquisition of a significant minority stake in Primary Wave Music as part of a new strategic partnership valued at over \$2 billion, and its additional \$1.7 billion capital funding commitment; funds affiliated with Apollo Global Management in a \$1.2 billion experiment by State Farm in ADT a portfolio company of Apollo; Kohlberg & Company in its acquisitions; it is a 50% stake in United States Infrastructure Corporation from Partners Group for an enterprise value of \$4.1 billion; funds managed by affiliates of Apollo Global Management and an investor group led by the Apollo funds, and including investment affiliates of J.F. Lehman & Company and Hill City Capital, in their take-private acquisition of Atlas Air Worldwide for an enterprise value of \$5.2 billion; Searchlight Capital Partners, alongside Rèv Worldwide, in their \$1 billion acquisition of the consumer business of Netspend from Global Payments; entities affiliated with Ares Capital Management in connection with Infrastructure and Energy Alternatives \$1.1 billion sale to MasTec; Clearlake Capital Group, L.P. in a consortium deal to acquisition of Oldcastle Building Envelope from CRH; 3G Capital in its \$6.8 billion sale to EQT; KPS Capital Partners in its \$3.45 billion sale to T. Rowe Price Group; Neustar in its \$3.1 billion acquisition of Oldcastle Building Envelope from CRH; 3G Capital in its \$1.1 billion acquisition of Oldcastle Building Stake in the Primary Products Business in North America and Latin America of Tate & Lyle; KPS Capital Partners and its portfolio company DexKo Global in the \$3.4 billion acquisition of Brookfield Business Partners; funds management in its \$1.1 billion merger with Athene; KPS Capital Partners in its \$1.1 billion acquisition of the EMEA food, aerosol and promotional packaging business from Crown Holding; Inspire Brands in its \$1.1.3 billion acquisition of

PAUL WEISS. RIFKIND, WHARTON & GARRISON LLP

M&A at a Glance

# Paul Weiss

**JANUARY 2023 | ISSUE 130** 

This publication is not intended to provide legal advice, and no legal or business decision should be based on its content. Questions concerning issues addressed in this memorandum should be directed to:

Matthew W. Abbott	Scott A. Barshay	Angelo Bonvino	Ariel J. Deckelbaum
+1-212-373-3402	+1-212-373-3040	+1-212-373-3570	+1-212-373-3546
<u>Email</u>	<u>Email</u>	<u>Email</u>	<u>Email</u>

Jeffrey D. Marell	Robert B. Schumer	Krishna Veeraraghavan	Taurie M. Zeitzer
+1-212-373-3105	+1-212-373-3097	+1-212-373-3661	+1-212-373-3353
<u>Email</u>	<u>Email</u>	<u>Email</u>	<u>Email</u>

Counsel Frances F. Mi, legal consultant Cara Grisin Fay, associates Susan Harling, Michelle Van Sleet and Evan Yoo, law clerk Dan Kang and staff attorney Max Melion contributed to this publication.

# Our M&A Partners

Matthew W. Abbott	lan M. Hazlett	Justin Rosenberg	Jeremy M. Veit
Edward T. Ackerman	Jeffrey L. Kochian	Kenneth M. Schneider	Michael Vogel
Scott A. Barshay	Kaisa Kuusk	Robert B. Schumer	Ramy J. Wahbeh
Angelo Bonvino	Andrew D. Krause	John M. Scott	Samuel J. Welt
Gerald Brant	David K. Lakhdhir	Brian Scrivani	Steven J. Williams
Ellen N. Ching	Brian C. Lavin	Kyle T. Seifried	Adam Wollstein
Ariel J. Deckelbaum	Xiaoyu Greg Liu	Cullen L. Sinclair	Bosco Yiu
Ross A. Fieldston	Jeffrey D. Marell	Megan Ward Spelman	Kaye N. Yoshino
Brian P. Finnegan	Alvaro Membrillera	Sarah Stasny	Tong Yu
Adam M. Givertz	Judie Ng Shortell	Laura C. Turano	Taurie M. Zeitzer
Neil Goldman	Austin Pollet	Krishna Veeraraghavan	

<sup>© 2023</sup> Paul, Weiss, Rifkind, Wharton & Garrison LLP. In some jurisdictions, this publication may be considered attorney advertising. Past representations are no guarantee of future outcomes.

PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP